Molecular resistance fingerprint of pemetrexed and platinum in a long-term survivor of mesothelioma

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Røe, Oluf Dimitri ^a,b   Szulkin, Adam ^c   Anderssen, Endre ^d   Flatberg, Arnar ^a   Sandeck, Helmut ^e   Amundsen, Tore ^a,e   Erlandsen, Sten Even ^a   Dobra, Katalin ^c   Sundstrøm, Stein Harald ^b  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b Levanger Hospital   (Norway)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY OF TROMSØ   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; CARBOPLATIN; CELL ADHESION MOLECULE; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKERATIN 19 FRAGMENT; DOXORUBICIN; FANCONI ANEMIA GROUP D2 PROTEIN; GEMCITABINE; KRT7 PROTEIN; MESSENGER RNA; NAVELBINE; PEMETREXED; PLATINUM; SMRP PROTEIN; THYMIDINE PHOSPHORYLASE; TS PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CASE REPORT; CELL CYCLE; CHEK2 GENE; CONTROLLED STUDY; CYTOKINESIS; DNA REPAIR; DOWN REGULATION; FANCD2 GENE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEUKOCYTE MIGRATION; LEUKOCYTE TRANSENDOTHELIUM MIGRATION; LIG3 GENE; LONG TERM SURVIVAL; MULTIPLE CYCLE TREATMENT; NT5C GENE; PLEURA MESOTHELIOMA; POLA2 GENE; POLD1 GENE; PROTEIN EXPRESSION; PROTEIN TARGETING; PRPF19 GENE; RECQ5 GENE; SURVIVAL TIME;

5'-NUCLEOTIDASE; ADULT; ANTINEOPLASTIC AGENTS; BIOPSY; CELL ADHESION; COHORT STUDIES; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOME-WIDE ASSOCIATION STUDY; GLUTAMATES; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PLATINUM; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84864658154     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040521     Document Type: Article

References (106)

1. Delgermaa V, Takahashi K, Park EK, Le GV, Hara T, et al. (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89: 716-724, 724A-724C.
2. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636-2644.
3. Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, et al. (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28: 1534-1539.
4. Ceppi P, Monica V, Righi L, Papotti M, Scagliotti GV, (2010) Emerging role of thymidylate synthase for the pharmacogenomic selection of patients with thoracic cancer. Int J Clin Pharmacol Ther 48: 481-482.
5. Zucali PA, Giovannetti E, Assaraf YG, Ceresoli GL, Peters GJ, et al. (2010) New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma. Ann Oncol 21: 1560-1561.
6. Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, et al. (2011) Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res 17: 2581-2590.
7. Martin LP, Hamilton TC, Schilder RJ, (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14: 1291-1295.
8. Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, et al. (2010) Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer 67: 57-68.
9. Roe OD, Anderssen E, Helge E, Pettersen CH, Olsen KS, et al. (2009) Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS One 4: e6554.
10. Reiner A, Yekutieli D, Benjamini Y, (2003) Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 19: 368-375.
11. Benjamini Y, Hochberg Y, (1995) Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society 57: 289-300.
12. Kanehisa M, Araki M, Goto S, Hattori M, Hirakawa M, et al. (2008) KEGG for linking genomes to life and the environment. Nucleic Acids Res 36: D480-484.
13. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.
14. Sandeck HP, Roe OD, Kjaerheim K, Willen H, Larsson E, (2010) Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry. Diagn Pathol 5: 47.
15. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, et al. (2008) Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. Lung Cancer 61: 235-243.
16. Schmitter D, Lauber B, Fagg B, Stahel RA, (1992) Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 51: 296-301.
17. Pelin-Enlund K, Husgafvel-Pursiainen K, Tammilehto L, Klockars M, Jantunen K, et al. (1990) Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. Carcinogenesis 11: 673-681.
18. Takada Y, Shinkai F, Kondo S, Yamamoto S, Tsuboi H, et al. (1994) Fluid shear stress increases the expression of thrombomodulin by cultured human endothelial cells. Biochem Biophys Res Commun 205: 1345-1352.
19. Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID, (2005) Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 11: 1294-1301.
20. Schultz RM, Chen VJ, Bewley JR, Roberts EF, Shih C, et al. (1999) Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol 26: 68-73.
21. van der Wilt CL, Backus HH, Smid K, Comijn L, Veerman G, et al. (2001) Modulation of both endogenous folates and thymidine enhance the therapeutic efficacy of thymidylate synthase inhibitors. Cancer Res 61: 3675-3681.
22. Castro M, (2003) Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol 21: 4066.
23. Muhale FA, Wetmore BA, Thomas RS, McLeod HL, (2011) Systems pharmacology assessment of the 5-fluorouracil pathway. Pharmacogenomics 12: 341-350.
24. Akiyama S, Furukawa T, Sumizawa T, Takebayashi Y, Nakajima Y, et al. (2004) The role of thymidine phosphorylase, an angiogenic enzyme, in tumor progression. Cancer Sci 95: 851-857.
25. Nakajima Y, Madhyastha R, Maruyama M, (2009) 2-Deoxy-D-ribose, a downstream mediator of thymidine phosphorylase, regulates tumor angiogenesis and progression. Anticancer Agents Med Chem 9: 239-245.
26. Devlin HL, Mack PC, Burich RA, Gumerlock PH, Kung HJ, et al. (2008) Impairment of the DNA repair and growth arrest pathways by p53R2 silencing enhances DNA damage-induced apoptosis in a p53-dependent manner in prostate cancer cells. Mol Cancer Res 6: 808-818.
27. Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, et al. (2011) Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma. J Hepatobiliary Pancreat Sci 18: 700-711.
28. Smid K, Bergman AM, Eijk PP, Veerman G, van Haperen VW, et al. (2006) Micro-array analysis of resistance for gemcitabine results in increased expression of ribonucleotide reductase subunits. Nucleosides Nucleotides Nucleic Acids 25: 1001-1007.
29. Huang A, Wright JA, (1994) Fibroblast growth factor mediated alterations in drug resistance, and evidence of gene amplification. Oncogene 9: 491-499.
30. Roe OD, Anderssen E, Sandeck H, Christensen T, Larsson E, et al. (2009) Malignant pleural mesothelioma: Genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets. Lung Cancer.
31. Tozlu-Kara S, Roux V, Andrieu C, Vendrell J, Vacher S, et al. (2007) Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen. J Mol Endocrinol 39: 305-318.
32. Chang P, Coughlin M, Mitchison TJ, (2005) Tankyrase-1 polymerization of poly(ADP-ribose) is required for spindle structure and function. Nat Cell Biol 7: 1133-1139.
33. Gelmini S, Quattrone S, Malentacchi F, Villari D, Travaglini F, et al. (2007) Tankyrase-1 mRNA expression in bladder cancer and paired urine sediment: preliminary experience. Clin Chem Lab Med 45: 862-866.
34. Cho SH, Goenka S, Henttinen T, Gudapati P, Reinikainen A, et al. (2009) PARP-14, a member of the B aggressive lymphoma family, transduces survival signals in primary B cells. Blood 113: 2416-2425.
35. Wang CL, Wang CI, Liao PC, Chen CD, Liang Y, et al. (2009) Discovery of retinoblastoma-associated binding protein 46 as a novel prognostic marker for distant metastasis in nonsmall cell lung cancer by combined analysis of cancer cell secretome and pleural effusion proteome. J Proteome Res 8: 4428-4440.
36. Fu J, Qin L, He T, Qin J, Hong J, et al. (2010) The TWIST/Mi2/NuRD protein complex and its essential role in cancer metastasis. Cell Res.
37. Mirchandani KD, D'Andrea AD, (2006) The Fanconi anemia/BRCA pathway: a coordinator of cross-link repair. Exp Cell Res 312: 2647-2653.
38. Lydeard JR, Jain S, Yamaguchi M, Haber JE, (2007) Break-induced replication and telomerase-independent telomere maintenance require Pol32. Nature 448: 820-823.
39. Ogi T, Limsirichaikul S, Overmeer RM, Volker M, Takenaka K, et al. (2010) Three DNA polymerases, recruited by different mechanisms, carry out NER repair synthesis in human cells. Mol Cell 37: 714-727.
40. Mocquet V, Laine JP, Riedl T, Yajin Z, Lee MY, et al. (2008) Sequential recruitment of the repair factors during NER: the role of XPG in initiating the resynthesis step. EMBO J 27: 155-167.
41. Timson DJ, Singleton MR, Wigley DB, (2000) DNA ligases in the repair and replication of DNA. Mutat Res 460: 301-318.
42. Moser J, Kool H, Giakzidis I, Caldecott K, Mullenders LH, et al. (2007) Sealing of chromosomal DNA nicks during nucleotide excision repair requires XRCC1 and DNA ligase III alpha in a cell-cycle-specific manner. Mol Cell 27: 311-323.
43. Catto JW, Abbod MF, Wild PJ, Linkens DA, Pilarsky C, et al. (2010) The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol 57: 398-406.
44. Li D, Suzuki H, Liu B, Morris J, Liu J, et al. (2009) DNA repair gene polymorphisms and risk of pancreatic cancer. Clin Cancer Res 15: 740-746.
45. Mahajan KN, Mitchell BS, (2003) Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Proc Natl Acad Sci U S A 100: 10746-10751.
46. Hu Y, Lu X, Zhou G, Barnes EL, Luo G, (2009) Recql5 plays an important role in DNA replication and cell survival after camptothecin treatment. Mol Biol Cell 20: 114-123.
47. Bucher N, Britten CD, (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer 98: 523-528.
48. Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, et al. (2010) RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol.
49. Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, et al. (2009) Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 7: 43.
50. Romagnoli S, Fasoli E, Vaira V, Falleni M, Pellegrini C, et al. (2009) Identification of potential therapeutic targets in malignant mesothelioma using cell-cycle gene expression analysis. Am J Pathol 174: 762-770.
51. Min SH, Goldman ID, Zhao R, (2008) Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed. Cancer Chemother Pharmacol 61: 819-827.
52. Lu Y, Wang L, Liu P, Yang P, You M, (2012) Gene-expression signature predicts postoperative recurrence in stage I non-small cell lung cancer patients. PLoS One 7: e30880.
53. Weis S, Cui J, Barnes L, Cheresh D, (2004) Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 167: 223-229.
54. Fujita T, Igarashi J, Okawa ER, Gotoh T, Manne J, et al. (2008) CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas. J Natl Cancer Inst 100: 940-949.
55. Hewitt KJ, Agarwal R, Morin PJ, (2006) The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6: 186.
56. Soini Y, Kinnula V, Kahlos K, Paakko P, (2006) Claudins in differential diagnosis between mesothelioma and metastatic adenocarcinoma of the pleura. J Clin Pathol 59: 250-254.
57. Vare P, Loikkanen I, Hirvikoski P, Vaarala MH, Soini Y, (2008) Low claudin expression is associated with high Gleason grade in prostate adenocarcinoma. Oncol Rep 19: 25-31.
58. Osanai M, Murata M, Nishikiori N, Chiba H, Kojima T, et al. (2006) Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res 66: 9125-9133.
59. Yang HJ, Chen JZ, Zhang WL, Ding YQ, (2010) Focal adhesion plaque associated cytoskeletons are involved in the invasion and metastasis of human colorectal carcinoma. Cancer Invest 28: 127-134.
60. Nelson ES, Folkmann AW, Henry MD, DeMali KA, (2011) Vinculin activators target integrins from within the cell to increase melanoma sensitivity to chemotherapy. Mol Cancer Res 9: 712-723.
61. Wegmann F, Petri B, Khandoga AG, Moser C, Khandoga A, et al. (2006) ESAM supports neutrophil extravasation, activation of Rho, and VEGF-induced vascular permeability. J Exp Med 203: 1671-1677.
62. Ludwig RJ, Zollner TM, Santoso S, Hardt K, Gille J, et al. (2005) Junctional adhesion molecules (JAM)-B and-C contribute to leukocyte extravasation to the skin and mediate cutaneous inflammation. J Invest Dermatol 125: 969-976.
63. Tot T, (2001) The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas. Cancer 92: 2727-2732.
64. De Angelis PM, Svendsrud DH, Kravik KL, Stokke T, (2006) Cellular response to 5-fluorouracil (5-FU) in 5-FU-resistant colon cancer cell lines during treatment and recovery. Mol Cancer 5: 20.
65. Fuhler GM, Baanstra M, Chesik D, Somasundaram R, Seckinger A, et al. (2010) Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res 316: 1816-1828.
66. Esposito I, Kayed H, Keleg S, Giese T, Sage EH, et al. (2007) Tumor-suppressor function of SPARC-like protein 1/Hevin in pancreatic cancer. Neoplasia 9: 8-17.
67. Bi X, Tong C, Dockendorff A, Bancroft L, Gallagher L, et al. (2008) Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 29: 1435-1440.
68. Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, et al. (2004) Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci U S A 101: 3456-3461.
69. Bongiovanni M, Cassoni P, De Giuli P, Viberti L, Cappia S, et al. (2001) p27(kip1) immunoreactivity correlates with long-term survival in pleural malignant mesothelioma. Cancer 92: 1245-1250.
70. Han S, Park K, Bae BN, Kim KH, Kim HJ, et al. (2003) Prognostic implication of cyclin E expression and its relationship with cyclin D1 and p27Kip1 expression on tissue microarrays of node negative breast cancer. J Surg Oncol 83: 241-247.
71. Wu MF, Hsiao YM, Huang CF, Huang YH, Yang WJ, et al. (2010) Genetic determinants of pemetrexed responsiveness and nonresponsiveness in non-small cell lung cancer cells. J Thorac Oncol 5: 1143-1151.
72. Gresner P, Gromadzinska J, Jablonska E, Kaczmarski J, Wasowicz W, (2009) Expression of selenoprotein-coding genes SEPP1, SEP15 and hGPX1 in non-small cell lung cancer. Lung Cancer 65: 34-40.
73. Fagerholm R, Hofstetter B, Tommiska J, Aaltonen K, Vrtel R, et al. (2008) NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40: 844-853.
74. Garate M, Wani AA, Li G, (2010) The NAD(P)H:Quinone Oxidoreductase 1 induces cell cycle progression and proliferation of melanoma cells. Free Radic Biol Med 48: 1601-1609.
75. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ, (2003) Selective killing of cancer cells by beta-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci U S A 100: 2674-2678.
76. Pink JJ, Planchon SM, Tagliarino C, Varnes ME, Siegel D, et al. (2000) NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J Biol Chem 275: 5416-5424.
77. Yamamoto G, Irie T, Aida T, Nagoshi Y, Tsuchiya R, et al. (2006) Correlation of invasion and metastasis of cancer cells, and expression of the RAD21 gene in oral squamous cell carcinoma. Virchows Arch 448: 435-441.
78. Atienza JM, Roth RB, Rosette C, Smylie KJ, Kammerer S, et al. (2005) Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol Cancer Ther 4: 361-368.
79. Tian XL, Kadaba R, You SA, Liu M, Timur AA, et al. (2004) Identification of an angiogenic factor that when mutated causes susceptibility to Klippel-Trenaunay syndrome. Nature 427: 640-645.
80. Long XH, Zhao ZQ, He XP, Wang HP, Xu QZ, et al. (2007) Dose-dependent expression changes of early response genes to ionizing radiation in human lymphoblastoid cells. Int J Mol Med 19: 607-615.
81. Hu Z, Huang G, Sadanandam A, Gu S, Lenburg ME, et al. (2010) The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Res 12: R18.
82. Kunz C, Focke F, Saito Y, Schuermann D, Lettieri T, et al. (2009) Base excision by thymine DNA glycosylase mediates DNA-directed cytotoxicity of 5-fluorouracil. PLoS Biol 7: e91.
83. Visnes T, Akbari M, Hagen L, Slupphaug G, Krokan HE, (2008) The rate of base excision repair of uracil is controlled by the initiating glycosylase. DNA Repair (Amst) 7: 1869-1881.
84. Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, et al. (2010) Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer. Cancer Res 70: 6639-6648.
85. Turton NJ, Judah DJ, Riley J, Davies R, Lipson D, et al. (2001) Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. Oncogene 20: 1300-1306.
86. Hassan KA, Ang KK, El-Naggar AK, Story MD, Lee JI, et al. (2002) Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 62: 6414-6417.
87. Ahmed KM, Li JJ, (2008) NF-kappa B-mediated adaptive resistance to ionizing radiation. Free Radic Biol Med 44: 1-13.
88. Corson TW, Zhu CQ, Lau SK, Shepherd FA, Tsao MS, et al. (2007) KIF14 messenger RNA expression is independently prognostic for outcome in lung cancer. Clin Cancer Res 13: 3229-3234.
89. Chen CH, Chien CY, Huang CC, Hwang CF, Chuang HC, et al. (2009) Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. Oncogene 28: 2723-2737.
90. Vecchi M, Confalonieri S, Nuciforo P, Vigano MA, Capra M, et al. (2008) Breast cancer metastases are molecularly distinct from their primary tumors. Oncogene 27: 2148-2158.
91. Cao D, Zhang Q, Wu LS, Salaria SN, Winter JW, et al. (2007) Prognostic significance of maspin in pancreatic ductal adenocarcinoma: tissue microarray analysis of 223 surgically resected cases. Mod Pathol 20: 570-578.
92. Yamamoto Y, Matsuyama H, Chochi Y, Okuda M, Kawauchi S, et al. (2007) Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer. Cancer Genet Cytogenet 174: 42-47.
93. Glinsky GV, (2006) Genomic models of metastatic cancer: functional analysis of death-from-cancer signature genes reveals aneuploid, anoikis-resistant, metastasis-enabling phenotype with altered cell cycle control and activated Polycomb Group (PcG) protein chromatin silencing pathway. Cell Cycle 5: 1208-1216.
94. Altieri DC, (2006) The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18: 609-615.
95. Kanwar RK, Cheung CH, Chang JY, Kanwar JR, (2010) Recent advances in anti-survivin treatments for cancer. Curr Med Chem 17: 1509-1515.
96. Gordon GJ, Mani M, Mukhopadhyay L, Dong L, Edenfield HR, et al. (2007) Expression patterns of inhibitor of apoptosis proteins in malignant pleural mesothelioma. J Pathol 211: 447-454.
97. Xia F, Lee CW, Altieri DC, (2008) Tumor cell dependence on Ran-GTP-directed mitosis. Cancer Res 68: 1826-1833.
98. Masuda TA, Inoue H, Nishida K, Sonoda H, Yoshikawa Y, et al. (2003) Cyclin-dependent kinase 1 gene expression is associated with poor prognosis in gastric carcinoma. Clin Cancer Res 9: 5693-5698.
99. Chen H, Huang Q, Dong J, Zhai DZ, Wang AD, et al. (2008) Overexpression of CDC2/CyclinB1 in gliomas, and CDC2 depletion inhibits proliferation of human glioma cells in vitro and in vivo. BMC Cancer 8: 29.
100. Garnis C, Campbell J, Davies JJ, Macaulay C, Lam S, et al. (2005) Involvement of multiple developmental genes on chromosome 1p in lung tumorigenesis. Hum Mol Genet 14: 475-482.
101. MacDermed DM, Khodarev NN, Pitroda SP, Edwards DC, Pelizzari CA, et al. (2010) MUC1-associated proliferation signature predicts outcomes in lung adenocarcinoma patients. BMC Med Genomics 3: 16.
102. Zalmas LP, Zhao X, Graham AL, Fisher R, Reilly C, et al. (2008) DNA-damage response control of E2F7 and E2F8. EMBO Rep 9: 252-259.
103. Mo ML, Chen Z, Li J, Li HL, Sheng Q, et al. (2010) Use of serum circulating CCNB2 in cancer surveillance. Int J Biol Markers 25.
104. Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S, (2007) Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 67: 1689-1695.
105. Lopez-Rios F, Chuai S, Flores R, Shimizu S, Ohno T, et al. (2006) Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. Cancer Res 66: 2970-2979.
106. Mountzios G, Terpos E, Dimopoulos MA, (2008) Aurora kinases as targets for cancer therapy. Cancer Treat Rev 34: 175-182.